Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients

CONCLUSION: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.PMID:34628408 | DOI:10.1159/000519043

Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research